An audit of antiretroviral treatment use in HIV-infected patients in a London clinic: the limitations of observational databases when auditing antiretroviral treatment use
- 1 April 2003
- journal article
- research article
- Published by Wiley in HIV Medicine
- Vol. 4 (2) , 87-93
- https://doi.org/10.1046/j.1468-1293.2003.00141.x
Abstract
To audit the use of antiretroviral (ARV) treatment in a large treatment clinic in the UK against the British HIV Association (BHIVA) ARV treatment guidelines. All patients under follow-up between 1st January 2000 and 1st January 2001 were included. The most recent CD4 count and HIV RNA level prior to 1st January 2001, and the nadir CD4 count and peak HIV RNA level over follow-up, were used to identify which patients should be receiving HAART according to the guidelines. One thousand two hundred and sixty-four patients were included in the analysis (63.8% homosexual, 29.0% heterosexual risk; 72.9% white; 79.2% male). Almost half of patients had ever had a CD4 count below 200 cells/ micro L and over 80% had previously had a viral load above 4 log10 HIV-1 RNA copies/mL. Under 2000 BHIVA guidelines, treatment would be recommended in 77.4% patients. Overall, 819 patients were receiving ARV therapy. Two hundred and eighty-five patients were not receiving treatment when guidelines suggest they should (including 33 patients who were receiving regimens not recommended in the guidelines). These patients were younger, less likely to be homosexual and had higher CD4 nadirs than those who were receiving ARV treatment. Almost half of these patients had previously received ARV therapy but were not currently receiving it. Only a small proportion of patients at our centre were not receiving ARV treatment in line with national guidelines. While genuine reasons may exist for these departures from optimal care, this may simply reflect the limitations of using observational databases when auditing treatment use in a clinic setting.Keywords
This publication has 10 references indexed in Scilit:
- Immunological changes during treatment interruptionsAIDS, 2003
- Long-term Exposure to Lifelong TherapiesJAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
- Initiating Antiretroviral Therapy During HIV InfectionJAMA, 2001
- British HIV Association (BHIVA) guidelines for the treatment of HIV‐infected adults with antiretroviral therapyHIV Medicine, 2001
- Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failureAIDS, 2000
- Changes in CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimensAIDS, 2000
- In Vivo Antagonism with Zidovudine plus Stavudine Combination TherapyThe Journal of Infectious Diseases, 2000
- British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapyHIV Medicine, 2000
- The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudineAIDS, 2000
- 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individualsThe Lancet, 1998